Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Beth Israel Deaconess Medical Center
Genentech, Inc.
Canadian Cancer Trials Group
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Genmab
Malaghan Institute of Medical Research
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
American Society of Clinical Oncology
Canadian Cancer Trials Group
National Cancer Institute (NCI)
Indiana University
Eli Lilly and Company
Prescient Therapeutics, Ltd.
Washington University School of Medicine
National Cancer Institute (NCI)
Eli Lilly and Company
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
University of Miami
University of Nebraska
Thomas Jefferson University
Columbia University
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Massachusetts General Hospital
University of California, Davis
City of Hope Medical Center
Massachusetts General Hospital
M.D. Anderson Cancer Center
Celgene
Ascentage Pharma Group Inc.
University of Washington
Thomas Jefferson University
Thomas Jefferson University